Research says approval of new drugs by NICE is 'doing more harm than good'

Research by health economists at the University of York has, for the first time, estimated the effects of changes in NHS expenditure on the health of all NHS patients.

This research has found that the 'threshold' used by the National Institute for Health and Care Excellence (NICE) when gauging the cost-effectiveness of new drugs is too high. This means that the approval of new drugs is doing more harm than good to NHS patents overall and the NHS is paying too much for new drugs.

Currently NICE uses a threshold of £30,000 per Quality Adjusted Life Year (QALY is a widely used measure of health that combines length and quality of life) to gauge whether the health benefits offered by a new drug are greater than the health likely to be lost because the additional resources required are not available to offer effective treatments to other NHS . The research found that this threshold is too high because £13,000 of NHS resources adds one QALY to the lives of NHS patients.

This means that more harm is being done to other NHS patients when NICE approves more costly drugs. For example, the approval of a new that costs the NHS an additional £10 million each year would offer benefits of 333 QALYs (at the current NICE threshold). This research shows it would also lead to the loss of 773 QALYs for other NHS patients with increased mortality in cancer, circulatory, respiratory or gastro-intestinal diseases and reduced quality of life in neurological diseases and mental (a net loss of 440 QALY for every £10m of additional NHS costs).

This research shows that the NHS is currently paying too much for new drugs because the amount the NHS can afford to pay for the benefits that new drugs offer is lower than previously thought. It also indicates the scale of the harm that has been done to other NHS patients of devoting £280m of NHS resources to the Cancer Drugs Fund in 2014/15 (a loss of 21,645 QALYs).

Co-author Professor Karl Claxton said: "The increasing pressure to approve new drugs more quickly at prices that are too high will only increase the harm done to NHS patients overall. The political pressure to support a multinational pharmaceutical sector cannot justify the real harm that has and will continue to be done to NHS patients."

Co-author Professor Mark Sculpher added: "The research demonstrates that the threshold to gauge cost-effectiveness and how much the NHS can afford to pay for benefits offered by is a scientific question that can be informed by evidence and analysis."

Explore further

Introducing 'more patient reality' into NHS spending decisions

More information: The report is available online:
Provided by University of York
Citation: Research says approval of new drugs by NICE is 'doing more harm than good' (2015, February 19) retrieved 6 October 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors